Molecular engineering of a cryptic epitope in Spike RBD improves manufacturability and neutralizing breadth against SARS-CoV-2 variants-Reference-Cited by-同舟云学术

Molecular engineering of a cryptic epitope in Spike RBD improves manufacturability and neutralizing breadth against SARS-CoV-2 variants

Published:2023-01 Issue:5 Volume:41 Page:1108-1118
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Rodriguez-Aponte Sergio A.,Dalvie Neil C.,Wong Ting Y.,Johnston Ryan S.,Naranjo Christopher A.,Bajoria Sakshi,Kumru Ozan S.,Kaur Kawaljit,Russ Brynnan P.,Lee Katherine S.,Cyphert Holly A.,Barbier Mariette,Rao Harish D.,Rajurkar Meghraj P.,Lothe Rakesh R.,Shaligram Umesh S.,Batwal Saurabh,Chandrasekaran Rahul,Nagar Gaurav,Kleanthous Harry,Biswas Sumi,Bevere Justin R.,Joshi Sangeeta B.,Volkin David B.,Damron F. Heath,Love J. Christopher

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference79 articles.

1. Sharing Technology and Vaccine Doses to Address Global Vaccine Inequity and End the COVID-19 Pandemic;Kavanagh;JAMA - J Am Med Assoc,2021

2. Burgos, R. M. et al. The race to a COVID-19 vaccine : opportunities and challenges in development and distribution Opportunities Vaccine development COVID-19 vaccines. 1–10 (2021) 10.7573/dic.2020-12-2.

3. Center for Disease Control and Prevention [CDC]. What You Need to Know About Variants. (2022).

4. In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains;Chen;Nature,2021

5. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies;Planas;Nat Med,2021

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Influenza virus strains expressing SARS-CoV-2 receptor binding domain protein confer immunity in K18-hACE2 mice;Vaccine: X;2024-10

2. Omicron XBB.1.16-Adapted Vaccine for COVID-19: Interim Immunogenicity and Safety Clinical Trial Results;Vaccines;2024-07-25

3. Immunogenicity and safety of an Omicron XBB.1.16 adapted vaccine for COVID-19: Interim results from a randomized, controlled, non-inferiority clinical trial;2024-04-19

4. SARS-CoV-2 RBD dimers elicit response comparable to VLPs in mice;2023-04-28